Neurocognitive Disorder with Lewy Bodies (NCDLB) and Parkinson's Disease patients frequently have synuclein (Lewy Body) pathology in their enteric nerve systems (ENS) (PD). Constipation, obstipation, and bowel impaction are examples of bowel immotility symptoms that can result from Lewy body disease in the ENS. It is discussed how synuclein (Lewy Body) disorder affects intestinal function specifically. These symptoms severely lower the patient's quality of life, which is difficult for both the patient and the caregivers. In theory, intestinal immobility in people with Lewy bodies can be considerably reduced or relieved with pharmacological treatment utilising acetylcholinesterase inhibitors (AChEIs). The justification for using the cholinergic agonist Donepezil to treat synuclein bowel dysfunction is discussed, along with a breakdown of how it works. The idea that AChEIs can lessen intestinal immotility brought on by Lewy bodies was investigated in longitudinal case studies. Donepezil showed effectiveness for reducing gastrointestinal dysfunction in Lewy body patients during a five-year period.
Author(s) Details:
Charles M. Lepkowsky,
Independent Practice, 1143 Deer Trail Lane, Solvang, CA 93463, United States.
Please see the link here: https://stm.bookpi.org/RABS-V9/article/view/8353
No comments:
Post a Comment